Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF

Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF

Objectives: This study assessed changes in B-type natriuretic peptide (BNP) among patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan (Sac/Val) according to standard prescribing information. Background: Through inhibition of neprilysin, Sac/Val may in...

Full description

Bibliographic Details
Main Authors: Claggett, B. (Author), Desai, A.S (Author), Fang, J.C (Author), Januzzi, J.L (Author), Mitchell, G.F (Author), Murphy, S.P (Author), Myhre, P.L (Author), Prescott, M.F (Author), Solomon, S.D (Author), Ward, J.H (Author)
Format: Article
Language:English
Published: Elsevier Inc. 2022
Subjects:
adult
aged
amino terminal pro brain natriuretic peptide
ARNI
arterial stiffness
Article
biomarker
blood level
blood sampling
BNP
clinical outcome
cohort analysis
controlled study
cyclic GMP
female
heart failure with reduced ejection fraction
heart ventricle remodeling
HFrEF
human
major clinical study
male
middle aged
prescription
sacubitril plus valsartan
sacubitril/valsartan
therapy effect
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items